Finally, our data provide evidence for a potential clinical utility for plasma levels of KIV or the BCKA/BCAA ratio to identify individuals with NAFLD/NASH that might be best suited to therapies that target the lipogenic machinery. The gene discussed is ARID4B; the disease is metabolic dysfunction-associated steatohepatitis.